Clinical trials: Remestemcel-L
Grade B aGVHD, Grade C aGVHD
A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
The study plans to treat at least 60 pediatric participants, male and female, between the ages of 2 months and 17 years inclusive with aGVHD following allogeneic hematopoietic stem cell transplant (HSCT) that has failed to…
- Conditions
- Grade B aGVHD, Grade C aGVHD, Grade D aGVHD
- Trial name
- NCT02336230
- Testing
- remestemcel-L
- Where
- 20 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mesoblast, Inc.
Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease
Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Ongoing safety assessment follow-up to Protocol MSB-GVHD001 (NCT02336230) of remestemcel-L treatment in pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant…
- Conditions
- Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease, Grade D Acute Graft Versus Host Disease
- Trial name
- NCT02652130
- Testing
- Remestemcel-L
- Where
- 20 sites in United States
- Volunteers
- 32 people
- Sponsor
- Mesoblast, Inc.